Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men

PHASE3CompletedINTERVENTIONAL
Enrollment

2,499

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
HIV Infections
Interventions
DRUG

daily TDF/FTC

daily oral medication

DRUG

Placebo

daily oral medication

Trial Locations (11)

7925

Desmond Tutu HIV Ctr. iPrEx CRS, Cape Town

50200

Research Institute for Health Sciences iPrEx CRS, Chiang Mai

60612

Stroger Hospital of Cook County/Core Center IPREX CRS, Chicago

94102

San Francisco Dept. of Public Health iPrEx CRS, San Francisco

02215

Fenway Community Health iPrEx CRS, Boston

21040-900

IPEC/FIOCRUZ iPrEx CRS, Rio de Janeiro

21941.590

Projeto Praca Onze, Universidade Federal do Rio de Janeiro iPrEx CRS, Rio de Janeiro

05403

Universidade de Sao Paulo iPrEx CRS, São Paulo

Unknown

Fundación Ecuatoriana Equidad, Guayaquil, iPrEx CRS, Guayaquil

Asociación Civil Selva Amazónica, Iquitos, iPrEx CRS, Iquitos

Investigaciones Médicas en Salud (INMENSA), Lince, iPrEx CRS, Lima

All Listed Sponsors
collaborator

Bill and Melinda Gates Foundation

OTHER

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00458393 - Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men | Biotech Hunter | Biotech Hunter